Tag: rare diseases

Rare Disease and Gene Therapy Threatened by Tariffs

In the face of mounting tariff threats from the Trump administration, the biotech industry has sounded a fervent alarm. The sector warns that advancements in rare disease, cell, and gene therapies—areas where innovation is sorely needed—are under serious threat. The issue at stake is not just about dollars and cents, but the broader public health […]

Trump Tariffs Threaten Rare Disease Cell and Gene Therapy

The biotech industry is sounding the alarm as Trump’s tariffs put rare disease cell and gene therapy at risk. With over 10,000 rare diseases still lacking FDA-approved therapies, companies like BioMarin are urging the preservation of incentives to sustain innovation. BioMarin, known for gene therapies like Roctavian for hemophilia A, is facing financial challenges despite […]